Actually, I didn’t state the obvious. You are focusing on competitors and what they are doing, rather than concentrating on what EIQ is achieving. You are also being lazy by relying on this forum for information instead of conducting your own research. It’s worth acknowledging that not all EIQ investors here are knowledgeable and capable of critical thinking. That is what’s truly obvious.In reality, how far competitors are in the FDA approval or commercialisation process has no bearing on EIQ. It adds no value to EIQ whatsoever. I therefore stand by my original comment: the company, and by extension its investors, should focus on EIQ, not its competitors.
EIQ Price at posting:
24.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)